Reference : Investigational glucagon receptor antagonists in Phase I and II clinical trials for d...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/216139
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
English
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Paquot, Nicolas mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques >]
Lefèbvre, Pierre mailto [Université de Liège - ULiège > > Relations académiques et scientifiques (Médecine) >]
2017
Expert Opinion on Investigational Drugs
26
12
1373-1389
Yes (verified by ORBi)
International
1354-3784
1744-7658
England
[en] Antisense oligonucleotides ; glucagon inhibition ; glucagon receptor ; monoclonal antibodies ; small-molecules ; type 2 diabetes
[en] INTRODUCTION: Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. However, glucagon receptor (GCGr) antagonists are currently investigated in clinical trials. Area covered: Following a brief description of the rationale for antagonizing GCGr in T2D, lessons from GCGr knock-out mice and pharmacological means to antagonize GCGr, a detailed description of the main results obtained with GCGr antagonists in Phase I-II clinical trials is provided. The development of several small molecules has been discontinued, while new ones are currently considered as well as innovative approaches such as monoclonal antibodies or antisense oligonucleotides inhibiting GCGr gene expression. Their potential benefits but also limitations are discussed. Expert opinion: The proof-of-concept that antagonizing GCGr improves glucose control in T2D has been confirmed in humans. Nevertheless, some adverse events led to stopping the development of some of these GCGr antagonists. New approaches seem to have a better benefit/risk balance, although none has progressed to Phase III clinical trials so far. Pharmacotherapy of T2D is becoming a highly competitive field so that GCGr antagonists should provide clear advantages over numerous existing glucose-lowering medications before eventually reaching clinical practice.
http://hdl.handle.net/2268/216139
10.1080/13543784.2017.1395020

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2017 EOID Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.pdfPublisher postprint1.87 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.